May 7 – 8, 2025 | NY Bar Association, New York, NY
Save 10% with IBRADEMP’s discount code: D10-999-IBRADEMP25
Online: https://bit.ly/43w5Ro7
Email: customerservice@americanconference.com
Phone: 1-888-224-2480
Navigating Global Ethics & Compliance Amid Seismic Enforcement Shifts in the Trump 2.0 Era. Newly Revamped to Keep Up with Rapid Change Under Trump 2.0, Discover Fresh Formats, Innovative Topics and Practical Guidance Tailored to the Life Sciences Industry:
- Who’s Doing What Since the Seismic Shift in FCPA Enforcement? How Life Sciences Companies Are Re-Ranking Risks and Rethinking Compliance Spend Amid Looming Uncertainty and Unintended Consequences
- Strengthening Your Culture of Compliance Without the “Stick” of FCPA Enforcement: Reevaluating Strategies for Buy-In, Incentives, Voluntary Disclosures and Your Whistleblower Policies
- Actionable Strategies for Doing Business in China: What It Takes to Thrive Amid the High-Risk Dynamics, New Healthcare Anti-Bribery Guidelines and Geopolitical Tensions
- Spotlight on Latin America, Cartels and TCOs: Strengthening Anti-Corruption Oversight of Life Sciences Company Business Operations in Latin America Amidst DOJ’s New Crackdown on Cartels & TCOs
- Utilizing AI and Data Analytics as Drivers of Compliance and Efficiencies: Life Sciences Companies Discuss New Approaches and Program Changes
- Join New Smaller-Group Third-Party Management Focus Groups: New Best Practices for Mitigating Corruption Risks of Third-Party Business Dealings in the Pharmaceutical, Biotech, CRO and Medical Device Contexts
Life sciences companies are navigating an increasingly complex anti-corruption landscape in 2025, marked by unprecedented shifts in FCPA enforcement priorities from the DOJ and sweeping policy changes under President Trump’s Executive Orders. As enforcement expectations evolve at home, global regulators are also tightening their grip, intensifying scrutiny, demanding greater corporate accountability, and heightening international enforcement standards.
It is now more important than ever that life sciences companies act decisively to reassess risk, recalibrate priorities, refine internal controls, and fortify global compliance frameworks.